# OnCo record biomed-valley-discoveries (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/biomed-valley-discoveries/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "biomed-valley-discoveries" ;
  schema:name "Biomed Valley Discoveries"@en ;
  schema:alternateName "BioMed Valley Discoveries, Inc."@en, "Biomed Valley Discoveries Inc."@en, "BVD"@en ;
  schema:description "Biomed Valley Discoveries is a Kansas City company owned through the Stowers Institute for Medical Research. Its main medicine, ulixertinib, blocks ERK, the last step of a growth signalling chain that is switched on in many cancers and in histiocytosis."@en ;
  schema:url <https://onco.cc/companies/biomed-valley-discoveries/>, <https://biomed-valley.com/> ;
  schema:dateModified "2026-11-04"^^xsd:date ;
  schema:citation <https://biomed-valley.com/>, <https://biomed-valley.com/ulixertinib/>, <https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=1173826>, <https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=398213> ;
  schema:addressCountry "US" ;
  onco:cancers <https://onco.cc/cancers/glioblastoma/>, <https://onco.cc/cancers/erdheim-chester-disease/> ;
  onco:sections <https://onco.cc/fronts/targeted-therapy/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:targets <https://onco.cc/targets/mapk1/>, <https://onco.cc/targets/mapk3/> ;
  onco:drugs <https://onco.cc/drugs/ulixertinib/> .